Trial
NCT01973062
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Case Comprehensive Cancer Center
Collaborators
—
Condition
Primary Central Nervous System Non-Hodgkin Lymphoma
Intervention
rituximab
Why stopped
Funding Unavailable
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-07-24